Dominique Elias1, Luca Viganò2, Franco Orsi3, Marta Scorsetti4, Tiziana Comito4, Jan Lerut5, Davide Cosola2, Guido Torzilli2. 1. Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France. 2. Department of Surgery, Division of Hepatobiliary and General Surgery, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Italy. 3. Department of Interventional Radiology, European Institute of Oncology, Milan, Italy. 4. Department of Radiotherapy, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Italy. 5. Department of Abdominal and Transplantation Surgery, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
Abstract
BACKGROUND: In recent years, the management of metastatic colorectal cancer has become more aggressive and more multidisciplinary. New treatment options have been proposed in addition to the standard approach of resection of liver metastases and chemotherapy. SUMMARY: Selected patients with synchronous limited peritoneal and liver disease (peritoneal cancer index <12 and <3 liver metastases) can be scheduled for aggressive treatment, including cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and liver resection. This approach has achieved survival benefits, even if the treatment is unlikely to be curative in most patients. Moreover, liver transplantation has been recently reconsidered for liver-only metastases, resulting in the de facto reinstatement of the chance of surgery for some unresectable patients. Even though indications for liver transplantation remain to be standardized, preliminary studies have reported extremely promising outcomes. Radio-embolization has proven to be an effective additional tool for the treatment of unresectable tumors, and its potential role in association with chemotherapy for resectable disease is currently being investigated. Stereotactic body radiation therapy is a safe, non-invasive, and effective therapeutic option for patients with inoperable oligometastatic disease. Thanks to recent technical progress, high radiation doses can now be delivered in fewer fractions with excellent local disease control and a low risk of radiation-induced liver injury. Finally, radiofrequency ablation (RFA) for colorectal metastases has become more effective, with results approaching those of surgical series. New interstitial treatments, such as microwave ablation and irreversible electroporation, could overcome some of the limitations of RFA, thereby further expanding indications and optimizing outcomes. KEY MESSAGES: Currently, a multidisciplinary approach to patients with colorectal liver metastases is mandatory. Aggressive surgical treatments should be integrated with all the available non-surgical options to maximize disease control and patient survival.
BACKGROUND: In recent years, the management of metastatic colorectal cancer has become more aggressive and more multidisciplinary. New treatment options have been proposed in addition to the standard approach of resection of liver metastases and chemotherapy. SUMMARY: Selected patients with synchronous limited peritoneal and liver disease (peritoneal cancer index <12 and <3 liver metastases) can be scheduled for aggressive treatment, including cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and liver resection. This approach has achieved survival benefits, even if the treatment is unlikely to be curative in most patients. Moreover, liver transplantation has been recently reconsidered for liver-only metastases, resulting in the de facto reinstatement of the chance of surgery for some unresectable patients. Even though indications for liver transplantation remain to be standardized, preliminary studies have reported extremely promising outcomes. Radio-embolization has proven to be an effective additional tool for the treatment of unresectable tumors, and its potential role in association with chemotherapy for resectable disease is currently being investigated. Stereotactic body radiation therapy is a safe, non-invasive, and effective therapeutic option for patients with inoperable oligometastatic disease. Thanks to recent technical progress, high radiation doses can now be delivered in fewer fractions with excellent local disease control and a low risk of radiation-induced liver injury. Finally, radiofrequency ablation (RFA) for colorectal metastases has become more effective, with results approaching those of surgical series. New interstitial treatments, such as microwave ablation and irreversible electroporation, could overcome some of the limitations of RFA, thereby further expanding indications and optimizing outcomes. KEY MESSAGES: Currently, a multidisciplinary approach to patients with colorectal liver metastases is mandatory. Aggressive surgical treatments should be integrated with all the available non-surgical options to maximize disease control and patient survival.
Entities:
Keywords:
Colorectal liver metastases and peritoneal carcinomatosis; Liver transplantation; Radioembolization; Radiofrequency ablation and microwave ablation; Stereotactic body radiation therapy
Authors: Universe Leung; Mithat Gönen; Peter J Allen; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: L Viganò; L Capussotti; P Majno; C Toso; A Ferrero; G De Rosa; L Rubbia-Brandt; G Mentha Journal: Br J Surg Date: 2015-01 Impact factor: 6.939
Authors: Robbert J de Haas; Dennis A Wicherts; Paola Andreani; Gérard Pascal; Faouzi Saliba; Philippe Ichai; René Adam; Denis Castaing; Daniel Azoulay Journal: Ann Surg Date: 2011-06 Impact factor: 12.969
Authors: Dennis A Wicherts; Rafael Miller; Robbert J de Haas; Georgia Bitsakou; Eric Vibert; Luc-Antoine Veilhan; Daniel Azoulay; Henri Bismuth; Denis Castaing; René Adam Journal: Ann Surg Date: 2008-12 Impact factor: 12.969
Authors: Alice Gillams; Nahum Goldberg; Muneeb Ahmed; Reto Bale; David Breen; Matthew Callstrom; Min Hua Chen; Byung Ihn Choi; Thierry de Baere; Damian Dupuy; Afshin Gangi; Debra Gervais; Thomas Helmberger; Ernst-Michael Jung; Fred Lee; Riccardo Lencioni; Ping Liang; Tito Livraghi; David Lu; Franca Meloni; Philippe Pereira; Fabio Piscaglia; Hyunchul Rhim; Riad Salem; Constantinos Sofocleous; Stephen B Solomon; Michael Soulen; Masatoshi Tanaka; Thomas Vogl; Brad Wood; Luigi Solbiati Journal: Eur Radiol Date: 2015-05-22 Impact factor: 5.315
Authors: Theresa Voglhuber; Kerstin A Eitz; Markus Oechsner; Marco M E Vogel; Stephanie E Combs Journal: BMC Cancer Date: 2021-07-06 Impact factor: 4.430